XXXX with nontransitional histology: a single-center experience.

@entity1 @entity3484 @entity4153 @entity5 @entity957 @entity189 @entity420
OBJECTIVES: To review our experience with @entity1 with @entity3484 of nonurothelial origin. @entity3484 of nonurothelial origin are uncommon entities. To our knowledge, no series of @entity1 with these @entity5 has been published in the past decade. METHODS: We reviewed the records at the University of Texas M. D. Anderson @entity5 Center from 1990 to 2004 to identify @entity1 with primary @entity5 of the upper urinary tract. We reviewed the @entity1 records to collect data on @entity5 subtype, treatment, recurrence, and survival. RESULTS: Sixteen @entity1 (1.9% of our database of @entity1 with @entity3484 ) were identified; 12 had @entity957 , 2 had @entity420 , 1 had @entity189 , and 1 had @entity4153 . The @entity5 were located in the renal pelvis in 10 and the ureter in 6. Of the 16 @entity1 , 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy. Fifteen of the @entity5 were pathologic Stage T3 or worse. Ten @entity1 received adjuvant chemotherapy. Of the 16 @entity1 , 9 died (1 of unknown causes), 4 were alive without disease, 2 were alive with disease, and 1 was alive at last follow-up with the disease status unknown. The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%. The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively. CONCLUSIONS: Primary @entity189 of the renal pelvis and ureter are rare. Our analysis suggests a poor prognosis for most @entity1 with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.
